Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

Propel Bio Management

Latest statistics and disclosures from Propel Bio Management's latest quarterly 13F-HR filing:

Central Index Key (CIK): 0001969764

Tip: Access up to 7 years of quarterly data

Positions held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for Propel Bio Management

Propel Bio Management holds 34 positions in its portfolio as reported in the December 2023 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Share Count	Share Price
Plains Gp Holdings Lp-cl Comm (PAGP)	18.1	$22M	1.4M	15.95	View chart
Applied Therapeutics Comm (APLT)	14.9	$18M	5.4M	3.35	View chart
Tscan Therapeutics Comm (TCRX)	10.1	$12M	2.1M	5.83	View chart
Madrigal Pharmaceuticals Comm (MDGL)	5.8	$6.9M	30k	231.38	View chart
Crinetics Pharmaceuticals In Comm (CRNX)	4.9	$5.9M	165k	35.58	View chart
Fulcrum Therapeutics Comm (FULC)	4.2	$5.1M	750k	6.75	View chart
Fidelity Inv Mmtrsy 1 680 Comm	4.0	$4.8M	4.8M	1.00	View chart
Phathom Pharmaceuticals Comm (PHAT)	3.4	$4.0M	443k	9.13	View chart
Day One Biopharmaceuticals I Comm (DAWN)	3.3	$4.0M	271k	14.60	View chart
Ardelyx Comm (ARDX)	3.1	$3.7M	594k	6.20	View chart
Athira Pharma Comm (ATHA)	3.0	$3.6M	1.5M	2.43	View chart
Telesat Corp Comm (TSAT)	2.5	$3.0M	291k	10.43	View chart
Simplify Enhanced Income Comm (HIGH)	2.4	$3.0M	120k	24.56	View chart
Akero Therapeutics Comm (AKRO)	1.9	$2.3M	100k	23.35	View chart
Vanguard Short-term Bond Comm (BSV)	1.8	$2.1M	28k	77.02	View chart
Ishares Ibonds Dec 2024 T Comm (IBDP)	1.8	$2.1M	85k	24.91	View chart
Ishares Mbs Etf Comm (MBB)	1.7	$2.1M	22k	94.08	View chart
Mirum Pharmaceuticals Comm (MIRM)	1.7	$2.1M	70k	29.52	View chart
Marinus Pharmaceuticals Comm (MRNS)	1.6	$2.0M	180k	10.87	View chart
Kura Oncology Comm (KURA)	1.5	$1.9M	130k	14.38	View chart
Avidity Biosciences Comm (RNA)	1.3	$1.6M	179k	9.05	View chart
Kymera Therapeutics Comm (KYMR)	1.2	$1.4M	56k	25.46	View chart
Spdr Port Shrt Trm Corp B Comm (SPSB)	1.1	$1.4M	46k	29.78	View chart
Kayne Anderson Energy Inf Comm (KYN)	1.1	$1.3M	147k	8.78	View chart
Eiger Biopharmaceuticals Comm	0.8	$986k	4.4M	0.22	View chart
Sutro Biopharma Comm (STRO)	0.7	$837k	195k	4.29	View chart
Ishares 0-5 Yr Inv Grd Comm (SLQD)	0.5	$598k	12k	49.20	View chart
Ishares Iboxx Investment Comm (LQD)	0.4	$493k	4.5k	110.66	View chart
X4 Pharmaceuticals Comm (XFOR)	0.4	$449k	535k	0.84	View chart
Cybin Comm (CYBN)	0.3	$349k	850k	0.41	View chart
Spdr Bloomberg Investment Comm (FLRN)	0.2	$284k	9.3k	30.59	View chart
Heron Therapeutics Comm (HRTX)	0.1	$177k	104k	1.70	View chart
Agios Pharmaceuticals Comm (AGIO)	0.1	$129k	5.8k	22.27	View chart
Chinook Therapeutics Inc Cvr Comm	0.0	$0	79k	0.00	View chart

Past Filings by Propel Bio Management

SEC 13F filings are viewable for Propel Bio Management going back to 2023

Propel Bio Management 2023 Q4 filed Feb. 14, 2024

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z